Radiopharmaceuticals Market Scope And Analysis

Radiopharmaceuticals Market Report Scope

Radiopharmaceuticals Market News and Recent Developments

The radiopharmaceuticals market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the radiopharmaceuticals market are listed below:

• Curium announced that it has entered into an agreement with Eczac?ba?? Holding and Bozlu Group for the acquisition of Eczac?ba??-Monrol Nuclear Product Co. (Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and PET & SPECT nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes. (Source: Curium, Press Release, April 2024)
• Novartis announced that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, US. (Source: Novartis, Press Release, January 2024)
• IBA Radiopharma Solutions, CMI Inc., and Life Molecular Imaging (LMI) announced that the Japanese Ministry of Health approved the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq (florbetaben 18F). Amyloid-PET imaging using agents like Neuraceq is used in the diagnosis of Alzheimer's disease and other forms of cognitive impairment. It detects amyloid plaques in the brain, characteristic markers of Alzheimer's disease. (Source: IBA, Press Release, December 2023)
• Telix received Health Canada approval for its Illuccix, a kit for the preparation of gallium (68Ga) gozetotide injection. The product can be used in staging and re-staging intermediate and high-risk prostate cancer and localizing tumor tissue in recurrent prostate cancer. Illuccix was the first PSMA PET imaging agent that was granted regulatory approval in Canada. Health Canada was the third regulatory body worldwide to approve Illuccix, which is commercially available in Australia and the US. (Source: Telix, Press Release, October 2022)
• GE Healthcare and Minerva Imaging entered into a strategic partnership to accelerate the commercial launch of targeted radionuclide therapies (theranostics). Radionuclide therapy is a form of precision medicine where a radioactive substance is administered through the bloodstream to target cancer cells and irradiate them specifically. This helps reduce potential side effects compared to traditional cancer therapies. (Source: GE Healthcare, Press Release, December 2021)

Radiopharmaceuticals Market Report Coverage and Deliverables

The “Radiopharmaceuticals Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

• Radiopharmaceuticals market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Radiopharmaceuticals market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Radiopharmaceuticals market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the radiopharmaceuticals market
• Detailed company profiles